Abstract
We present results for νμ oscillation in the KEK to Kamioka (K2K) long-baseline neutrino oscillation experiment. K2K uses an accelerator-produced νμ beam with a mean energy of 1.3 GeV directed at the Super-Kamiokande detector. We observed the energy-dependent disappearance of vmu;, which we presume have oscillated to ντ. The probability that we would observe these results if there is no neutrino oscillation is 0.0050% (4.0σ).
Original language | English |
---|---|
Article number | 081802 |
Journal | Physical Review Letters |
Volume | 94 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2005 Mar 4 |
Externally published | Yes |
ASJC Scopus subject areas
- Physics and Astronomy(all)
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Evidence for muon neutrino oscillation in an accelerator-based experiment'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Physical Review Letters, Vol. 94, No. 8, 081802, 04.03.2005.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Evidence for muon neutrino oscillation in an accelerator-based experiment
AU - Aliu, E.
AU - Andringa, S.
AU - Aoki, S.
AU - Argyriades, J.
AU - Asakura, K.
AU - Ashie, R.
AU - Berns, H.
AU - Bhang, H.
AU - Blondel, A.
AU - Borghi, S.
AU - Bouchez, J.
AU - Burguet-Castell, J.
AU - Casper, D.
AU - Cavata, C.
AU - Cervera, A.
AU - Cho, K. O.
AU - Choi, J. H.
AU - Dore, U.
AU - Espinal, X.
AU - Fechner, M.
AU - Fernandez, E.
AU - Fukuda, Y.
AU - Gomez-Cadenas, J.
AU - Gran, R.
AU - Hara, T.
AU - Hasegawa, M.
AU - Hasegawa, T.
AU - Hayashi, K.
AU - Hayato, Y.
AU - Helmer, R. L.
AU - Hill, J.
AU - Hiraide, K.
AU - Hosaka, J.
AU - Ichikawa, A. K.
AU - Iinuma, M.
AU - Ikeda, A.
AU - Inagaki, T.
AU - Ishida, T.
AU - Ishihara, K.
AU - Ishii, T.
AU - Ishitsuka, M.
AU - Itow, Y.
AU - Iwashita, T.
AU - Jang, H. I.
AU - Jeon, E. J.
AU - Jeong, I. S.
AU - Joo, K.
AU - Jover, G.
AU - Jung, C. K.
AU - Kajita, T.
AU - Kameda, J.
AU - Kaneyuki, K.
AU - Kato, I.
AU - Kearns, E.
AU - Kerr, D.
AU - Kim, C. O.
AU - Khabibullin, M.
AU - Khotjantsev, A.
AU - Kielczewska, D.
AU - Kim, J. Y.
AU - Kim, S.
AU - Kitching, P.
AU - Kobayashi, K.
AU - Kobayashi, T.
AU - Konaka, A.
AU - Koshio, Y.
AU - Kropp, W.
AU - Kubota, J.
AU - Kudenko, Y.
AU - Kuno, Y.
AU - Kutter, T.
AU - Learned, J.
AU - Likhoded, S.
AU - Lim, I. T.
AU - Loverre, P. F.
AU - Ludovici, L.
AU - Maesaka, H.
AU - Mallet, J.
AU - Mariani, C.
AU - Maruyama, T.
AU - Matsuno, S.
AU - Matveev, V.
AU - Mauger, C.
AU - McConnel, K.
AU - McGrew, C.
AU - Mikheyev, S.
AU - Minamino, A.
AU - Mine, S.
AU - Mineev, O.
AU - Mitsuda, C.
AU - Miura, M.
AU - Moriguchi, Y.
AU - Morita, T.
AU - Moriyama, S.
AU - Nakadaira, T.
AU - Nakahata, M.
AU - Nakamura, K.
AU - Nakano, I.
AU - Nakaya, T.
AU - Nakayama, S.
AU - Namba, T.
AU - Nambu, R.
AU - Nawang, S.
AU - Nishikawa, K.
AU - Nitta, K.
AU - Nova, F.
AU - Novella, P.
AU - Obayashi, Y.
AU - Okada, A.
AU - Okumura, K.
AU - Oser, S. M.
AU - Oyama, Y.
AU - Pac, M. Y.
AU - Pierre, F.
AU - Rodriguez, A.
AU - Saji, C.
AU - Sakuda, M.
AU - Sanchez, F.
AU - Sarrat, A.
AU - Sasaki, T.
AU - Scholberg, K.
AU - Schroeter, R.
AU - Sekiguchi, M.
AU - Sharkey, E.
AU - Shiozawa, M.
AU - Shiraishi, K.
AU - Sitjes, G.
AU - Smy, M.
AU - Sobel, H.
AU - Stone, J.
AU - Sulak, L.
AU - Suzuki, A.
AU - Suzuki, Y.
AU - Takahashi, T.
AU - Takenaga, Y.
AU - Takeuchi, Y.
AU - Taki, K.
AU - Takubo, Y.
AU - Tamura, N.
AU - Tanaka, M.
AU - Terri, R.
AU - T'Jampens, S.
AU - Tornero-Lopez, A.
AU - Totsuka, Y.
AU - Ueda, S.
AU - Vagins, M.
AU - Walter, C. W.
AU - Wang, W.
AU - Wilkes, R. J.
AU - Yamada, S.
AU - Yamamoto, S.
AU - Yanagisawa, C.
AU - Yershov, N.
AU - Yokoyama, H.
AU - Yokoyama, M.
AU - Yoo, J.
AU - Yoshida, M.
AU - Zalipska, J.
N1 - Funding Information: This work was supported by Gilead Sciences, Inc. Writing support was provided by Impact Communication Partners and funded by Gilead Sciences, Inc. Funding Information: Conflict-of-interest disclosure: S.T.O. has served as a consultant for Incyte, Gilead Sciences, Novartis, Celgene/Bristol Myers Squibb, Blueprint Medicines, Kartos Therapeutics, Disc Medicine, and CTI BioPharma. M.T. has received clinical research funding from AbbVie, Novartis, CTI BioPharma, Constellation Pharmaceuticals, Celgene, and NS Pharma. A.T.G. has served as a consultant for CTI BioPharma, Celgene, Kartos Therapeutics, Promedior, and Pfizer. V.G. has served as a consultant for Novartis, Celgene, Sierra Oncology, and Pfizer and has received research funding from Novartis and Incyte. S.V. has received research support for conduct of clinical studies from Incyte, Roche, NS Pharma, Celgene, Gilead Sciences, Promedior, CTI BioPharma, Genentech, Blueprint Medicines, Novartis, Sierra Oncology, Pharma Essentia, AstraZeneca, Ital Pharma, Protagonist Therapeutics, Constellation Pharmaceuticals, Kartos Therapeutics, Prelude Therapeutics, AbbVie, and Telios Pharmaceuticals and has received consulting fees from Constellation Pharmaceuticals, Sierra Oncology, Incyte, Novartis, and Celgene. R.M. has served as a consultant for Novartis, Sierra Oncology, and La Jolla Pharmaceutical and has received research funding from Incyte, CTI BioPharma, Celgene, and Genentech. C.B.M. has served as a consultant for Incyte, Verastem Oncology, and CTI BioPharma. A.G.F. serves on the speaker’s bureau for Funding Information: Incyte. M.L.H. has served as a consultant for Blueprint Medicines, Roche, Shire, and Partner Therapeutics and has received research funding from Blueprint Medicine, Bristol Myers Squibb, Constellation Pharmaceuticals, CTI BioPharma, Deciphera Pharmaceuticals, Gilead Sciences, Incyte, Janssen, Novartis, Onconova Therapeutics, and Roche. C.O. has served on an advisory board for AbbVie . M.O.A. has received research funding from Gilead Sciences, Incyte, Janssen, CTI BioPharma, and Samus Therapeutics. T.G. has served as a consultant for Sierra Oncology, Keryx/Akebia, Ionis, Vifor Pharma, American Regent, Silarus Therapeutics, Gossamer Bio, and Disc Medicine; has received research funding from Sierra
PY - 2005/3/4
Y1 - 2005/3/4
N2 - We present results for νμ oscillation in the KEK to Kamioka (K2K) long-baseline neutrino oscillation experiment. K2K uses an accelerator-produced νμ beam with a mean energy of 1.3 GeV directed at the Super-Kamiokande detector. We observed the energy-dependent disappearance of vmu;, which we presume have oscillated to ντ. The probability that we would observe these results if there is no neutrino oscillation is 0.0050% (4.0σ).
AB - We present results for νμ oscillation in the KEK to Kamioka (K2K) long-baseline neutrino oscillation experiment. K2K uses an accelerator-produced νμ beam with a mean energy of 1.3 GeV directed at the Super-Kamiokande detector. We observed the energy-dependent disappearance of vmu;, which we presume have oscillated to ντ. The probability that we would observe these results if there is no neutrino oscillation is 0.0050% (4.0σ).
UR - http://www.scopus.com/inward/record.url?scp=18244367130&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18244367130&partnerID=8YFLogxK
U2 - 10.1103/PhysRevLett.94.081802
DO - 10.1103/PhysRevLett.94.081802
M3 - Article
AN - SCOPUS:18244367130
SN - 0031-9007
VL - 94
JO - Physical Review Letters
JF - Physical Review Letters
IS - 8
M1 - 081802
ER -